Alegre, Brazil; Muscle Fiber Irregularity Index, MFII). The index works as a threshold to set to fibers and assessed its area and its regularity (the last through an index named the Image Pro Plus software (Media Cybernetics, China), we segmented muscle CIA and 8 controls were euthanized for muscle evaluation in mild disease and, disease. 16 healthy mice were used as control. After 25 days CIA induction, 8 cle strength using grip strength test and clinical disease score after onset of a booster after 18 days induction. Along experimental phase, we evaluated mus-
in CIA.

Objectives: similar to human RA, thereby it is a convenient model to study the disease impact in the literature. CIA is a RA mice model characterized by loss of muscle mass and correlate the morphological features with the muscle functional performance.

Acknowledgments: none

Disclose of Interests: cristiana barbar: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, Consultant of: Novartis, Gilead, Lilly, Sanofi, Celgene, Speakers bureau: Lilly, Lilly: cristina garufi: None declared, Ilaria Duca: None declared, fulvia ceccarelli: None declared, Tania Colasanti: None declared, Marta Vomero: None declared, cristiano alessandri Grant/research support from: Lilly, Eduardo Chiela: None declared, Ricardo Xavier Disclosure of Interests: Bárbara Bartkoski: None declared, Jordana Miranda de Souza Silva: None declared, Eduard Chielo: None declared, Ricardo Xavier Consultant of: AbbVie, Pfizer, Novartis, Janssen, Eli Lilly, Roche

DOI: 10.1136/annrheumdis-2020-eular.5995

AB0086

NEW METHOD TO ASSESS SKELETAL MUSCLE ATROPHY IN COLLAGEN INDUCED ARTHRITIS (CIA) MODEL

B. Bartkoski1,2,3, J. Miranda de Souza Silva3,4, E. Chielo3,5, R. Xavier1,3,5, 1Hospital de Clínicas de Porto Alegre, Brazil, Porto Alegre, Brazil; 2Servicio de Reumatologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; 3Laboratório de Doenças Autoimunes, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; 4Hospital de Clínicas de Porto Alegre, Brazil, Porto Alegre, Brazil; 5Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; 6Departamento de Ciências Morfológicas, ICBS, Serviço de Pesquisa Experimental, Porto Alegre, Brazil

Background: Muscle quality in rheumatoid arthritis (RA) is a new concept that involves morphological features and function. A measurement that associates cell morphology with clinical and physical parameters has not been reported in the literature. CIA is a RA mice model characterized by loss of muscle mass similar to human RA, thereby it is a convenient model to study the disease impact in muscle physiology.

Objectives: Develop an index to measure the morphometry of muscle fibers and correlate the morphological features with the muscle functional performance in CIA.

Methods: 18 DBA/1J mice were induced using complete Freund’s adjuvant and a booster after 18 days induction. Along experimental phase, we evaluated muscle strength using grip strength test and clinical disease score after onset of disease. 16 healthy mice were used as control. After 25 days CIA induction, 8 CIA and 8 controls were euthanized for muscle evaluation in severe disease. Tibialis anterior were collected for myofiber histological analysis. Using the Image Pro Plus software (Media Cybernetics, China), we segmented muscle fibers and assessed its area and its regularity (the last through an index named Muscle Fiber Irregularity Index, MFII). The index works as a threshold to set to screen the degree of normal, atrophic and hypertrophic based on the morphometry if muscle fibers. Values are compared to area and shape of control (healthy) fibers. Frequency analysis and Pearson Correlations were used and statistical significance was considered as p<0.05.

Results: We found 1.5% atrophic muscle fibers in control animals. Mild CIA showed the same atrophic muscle fibers percentage compared to control. However, severe CIA showed 11.8% of atrophic muscle fibers. Decrease muscle strength in CIA over time were associated with a greater atrophic muscle fiber proportion (r=0.8, p=0.021) and increased disease score (r=0.8, p=0.019).

Conclusion: Here we developed a new, objective method applied to screen for muscle quality through the morphometry of muscle fibers. Muscular Morphometric Analysis (MusMA) has potential to be used in combination with clinical parameters in several human pathophysiological analysis. Besides that, we can speculate that although muscle strength is associated with atrophic cell percentage, loss of strength does not only depend of atrophy, but disease activity also seems to influence muscle strength reduction.


AB0087

FEATURES OF ANTIPHOSPHOLIPID ANTIBODIES SPECTRUM IN PATIENTS WITH RHEUMATOID ARTHRITIS

N. Bashlakova1, T. Tyabut2, A. Buglova2, A. Trushyna3, 1Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus; 2Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus; 3Belarusian State Medical University, Minsk, Belarus

Background: Currently, some data have been accumulated on the participation of antiphospholipid antibodies (aPL) in the development of thrombotic complications in patients with autoimmune rheumatic diseases (ARD), in particular, in patients with systemic lupus erythematosus (SLE). The most studied aPL in this pathology are IgG and IgM antibodies to cardiolipin (aCL), anti-β2-glycoprotein 1 antibodies (aβ2-GP-1), lupus anticoagulant (LA). The participation of IgG and IgM antibodies to prothrombin (aPT) and to annexin V (aANV), antibodies to oxidized low density lipoproteins (aOxLDL) in hypercoagulation and the development of thrombosis is also discussed. However, the studies focusing on the investigation of aPL in patients with rheumatoid arthritis (RA) are few.

Objectives: To estimate the levels and the frequency of occurrence of aPL in patients with RA in comparison to the SLE patients and the control group.

Methods: The study included 85 female patients with ARD (RA (n=45), mean age 43.0 (33.0; 52.0) years old, disease duration 9.0 (5.0; 13.0) years, disease activity (DAS28= 5.37 (4.69; 5.89) points) and SLE (n=40), mean age 33.5 (27.5; 44.5) years old, disease duration 8.0 (5.0; 14.5) years, disease activity SLE-DAI-2K 7.0 (4.0; 11.5) points. Fifty four healthy women (mean age 38.5 (35.0; 46.0) years old) formed the control group.

The levels of antiphospholipid antibodies (IgG/IgM aCL, aβ2-GP-1, aANV and aPT, aOxLDL) were determined with ELISA according to the instruction of a manufacturer. LA was determined by one-stage clotting assay using reagents for screening and confirmation (Technochot LA Screen and Technochot LA Confirm, Austria).

Results: The frequency of occurrence of elevated levels of all investigated aPL in patients with RA was similar to SLE patients and was revealed in 57.8% of cases for IgG/IgM aCL, 44.4% for IgG/IgM aβ2-GP-1, 26.7% for IgG/IgM aANV, 8.9% for aPT, 52.6% for LA, 64.4% for aOxLDL. The patients with SLE had an increased levels of IgG/IgM aCL in 60.0% of cases, IgG/IgM aβ2-GP-1 in 57.5%, IgG/IgM aANV in 15.0%, IgG/IgM aPT in 175%, high levels of LA in 68.8%, of IgG aOxLDL – in 80.0% of cases. The control group had a high levels of IgG/IgM aCL in 1.8%, IgG/IgM aβ2-GP-1 in 3.7%, IgG/IgM aANV in 5.6%, IgG/IgM aPT in 1.8%, high levels of IgG aOxLDL – in 42.6% of cases. None of the controls had an increased level of LA. The frequency of occurrence of elevated levels of aPL and their mean levels in both groups of patients with ARD was higher as compare to the control group (р<0.05).


AB0087